Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS20045027HPVENSG00000149295.14protein_codingDRD2NoNo1813P14416
TVIS20049925HPVENSG00000149295.14protein_codingDRD2NoNo1813P14416
TVIS20025509HPVENSG00000149295.14protein_codingDRD2NoNo1813P14416
TVIS20049443HPVENSG00000149295.14protein_codingDRD2NoNo1813P14416
TVIS44014966HTLV-1ENSG00000149295.14protein_codingDRD2NoNo1813P14416
TCGA Plot Options
Drug Information
GeneDRD2
DrugBank IDDB00850
Drug NamePerphenazine
Target IDBE0000756
UniProt IDP14416
Regulation Typeantagonist
PubMed IDs11873706; 7508675; 7828655; 11752352; 15007534; 2573104
CitationsSeeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38.@@Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I: Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand. 1993 Dec;88(6):395-402.@@Qin ZH, Weiss B: Dopamine receptor blockade increases dopamine D2 receptor and glutamic acid decarboxylase mRNAs in mouse substantia nigra. Eur J Pharmacol. 1994 Sep 15;269(1):25-33.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Talvik M, Nordstrom AL, Larsen NE, Jucaite A, Cervenka S, Halldin C, Farde L: A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration. Psychopharmacology (Berl). 2004 Sep;175(2):148-53. Epub 2004 Mar 6.@@Farde L, Wiesel FA, Nordstrom AL, Sedvall G: D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology (Berl). 1989;99 Suppl:S28-31.
GroupsApproved
Direct ClassificationPhenothiazines
SMILESOCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
Pathways
PharmGKBPA450882
ChEMBLCHEMBL567